This author has not written his bio yet.
But we are proud to say that Etira contributed 32 entries already.
San Antonio, TX – March 23, 2026. We are pleased to present our new open-access paper in Biomolecules (link here). Our paper shows activity of ERX-41 in Inflammatory breast cancer (IBC), a rare (2–4%) extremely aggressive subset of breast cancer, marked by rapid onset, early metastasis, and dismal 5-year survival (~40%) despite multimodal therapy. Key […]
San Antonio TX, February 06, 2026 Introducing ERX-208 – our supercharged ERX-41 analog for ovarian cancer! Publication in Oncogene shows the same powerful MOA of inducing uncompensated ER stress, but ERX-208 delivers dramatically higher potency by engaging LIPA across a vastly larger interaction surface. Link to paper; https://lnkd.in/eJ2EJDRd
Congratulations to Dr Annalisa Jenkins OBE, a member of Etira’s Board of Directors, who has been appointed an Officer of the Order of the British Empire (OBE) in The King’s New Year Honours for her contributions to the life sciences.
San Antonio, TX – November 18, 2025. Etira Founder Professor Ratna Vadlamudi delivered a compelling, deeply personal narrative as the featured speaker at the Health Cell State of the Industry event at the Tobin Center in San Antonio.
Dallas, Texas — June 26, 2025: Etira, a clinical-stage biopharmaceutical company aiming to develop cancer therapies, announced today that the first patient has been successfully treated at Dose Level Four (DL4) in its ongoing Phase 1 clinical trial of investigational drug ERX-315 (NCT06533332). ERX-315 is a first-in-class small-molecule therapy designed to induce endoplasmic reticulum (ER) […]
Sydney, Australia – June 2, 2025: Etira, a clinical-stage biopharmaceutical company focused on developing cancer therapies, announced the activation of a new trial site at Macquarie University Hospital (MUH) in Sydney, New South Wales. The facility joins The Kinghorn Cancer Centre and Cancer Research South Australia as an active recruitment site for Etira’s ongoing ERX-315-001 […]
Chicago, IL – April 30, 2025: Presenters of two abstracts with preclinical data on ERX-208 and ERX-315 have won awards at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. Adriana Baker, who presented a poster titled “ERX-315 targets LIPA and potently causes catastrophic endoplasmic reticulum stress in multiple subtypes of hepatocellular […]
Chicago, IL – April 23, 2025: Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as a powerful breakthrough in ovarian cancer treatment, rigorously assess synergy of ERX-208 with FDA-approved drugs, and validate […]
Adelaide, Australia – March 17, 2025: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, has now activated a second site for recruitment of patients for the ERX-315-001 clinical trial at Cancer Research South Australia (CRSA) located in Adelaide, South Australia. CRSA was activated after the site initiation visit to review study related protocol, procedures, […]
Sydney, Australia – February 20, 2025: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, announced today that a patient has been successfully dosed at Dose Level Three (DL3) of ERX-315 in its Phase 1 trial (NCT06533332). ERX-315 is Etira’s first-in-class small molecule drug designed to induce endoplasmic reticulum stress leading to death of cancer […]
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247
Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247